GCGR and Alzheimer disease: After administration of Triple GLP-1/GIP/glucagon receptor agonist, learning and memory impairment of AD models (APP/PS1 mice and 3×Tg-AD mice) was improved, amyloid plaques, tau pathology, inflammation response and oxidative stress in brains of two AD models were ameliorated (239–241).